Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 14/20 | 0.72 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.72 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48942 | 0.84 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48710 | 0.83 | PIK3CG (0.82) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48461 | 0.80 | PIK3CG (0.76) | PIK3CGPIK3CDPIK3CAPIK3CBKDM4E | |
| SCHEMBL2324376 | 0.79 | NPC1 (0.46) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48393 | 0.79 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CBKDM4E | |
| SCHEMBL12992093 | 0.78 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CAPIK3CBALDH1A1 | |
| SCHEMBL2948810 | 0.78 | PIK3CD (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL10670937 | 0.77 | PIK3CG (0.72) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL2961300 | 0.77 | PIK3CD (0.56) | PIK3CGPIK3CDPIK3CAPIK3CBPI4KB | |
| SCHEMBL48302 | 0.76 | MAPT (0.78) | PIK3CGPIK3CDPIK3CAPIK3CBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357179-A1 | Thiazol-2-yl organic compounds | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| CN-101374823-A | Organic compounds | NOVARTIS AG (CH) | 2009-02-25 | — | — | CN | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| EP-1966175-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | PIK3CG 10/4885PIK3CD 3/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.